Scalper1 News
The long-awaited report from the Senate Finance committee on Gilead Sciences’ (GILD) pricing of its hepatitis C drugs came out Tuesday, and as expected, it was highly critical. Sens. Ron Wyden, D-Ore., and Chuck Grassley, R-Iowa, said in the spring of 2014 that they would investigate Gilead’s pricing policies after Gilead priced its new hepatitis C drug Sovaldi at $84,000 for a 12-week regimen. Their criticism of the price led Gilead and nearly Scalper1 News
Scalper1 News